Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Want to see AMRX full AI Analyst Report?
Top Page
Amneal Pharmaceuticals
(NASDAQ:AMRX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$13.50
▼(-2.95% Downside)
Action:ReiteratedDate:04/22/26
The score is driven primarily by improving financial fundamentals (notably cash generation and recent deleveraging) and a constructive earnings outlook with margin/EPS expansion. These positives are weighed down by a rich valuation (high P/E, no dividend) and only moderately supportive technicals, with corporate events adding modest net positivity but including settlement-related risk.
Positive Factors
Free cash flow generation
Operating and free cash flow rebounded strongly since 2023, with double-digit free-cash-flow growth in 2025. Durable positive cash conversion funds capex (~$110M), supports launches, deleveraging and M&A without reliance on short-term capital markets, underpinning multi-year financial flexibility.
Negative Factors
Execution & timing risk
Company growth relies on numerous forward-looking milestones—regulatory approvals, complex manufacturing ramps and multiple product launches. Each milestone carries regulatory, supply‑chain and commercial execution risk, so delays or missteps could defer margin expansion and cash flows for years rather than quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow generation
Operating and free cash flow rebounded strongly since 2023, with double-digit free-cash-flow growth in 2025. Durable positive cash conversion funds capex (~$110M), supports launches, deleveraging and M&A without reliance on short-term capital markets, underpinning multi-year financial flexibility.
Read all positive factors
Amneal Pharmaceuticals (AMRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.01B
Dividend YieldN/A
Average Volume (3M)1.85M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth7.64%
EPS GrowthN/A
CountryUS
Employees8,300
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding318,999,020
10 Day Avg. Volume1,393,991
30 Day Avg. Volume1,846,768
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)-55.77
Price to Sales (P/S)1.31
P/FCF Ratio14.63
Enterprise Value/Market Cap1.62
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit5.85
Enterprise Value/Ebitda10.78
Forecast
1Y Price Target
$17.25Price Target Upside24.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Amneal Pharmaceuticals Business Overview & Revenue Model
Company Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through thr...
How the Company Makes Money
Amneal makes money primarily by selling pharmaceutical products to wholesalers, pharmacies, hospitals, distributors, and other healthcare-channel customers. Its core revenue stream is the sale of generic prescription drugs: it develops or in-licen...
Amneal Pharmaceuticals Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
41
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.02B | 2.79B | 2.39B | 2.21B | 2.09B |
| Gross Profit | 1.14B | 1.02B | 863.87M | 791.46M | 768.97M |
| EBITDA | 603.87M | 439.77M | 500.78M | 440.21M | 401.10M |
| Net Income | 72.06M | -116.89M | -83.99M | -129.99M | 10.62M |
Balance Sheet | |||||
| Total Assets | 3.68B | 3.50B | 3.47B | 3.80B | 3.94B |
| Cash, Cash Equivalents and Short-Term Investments | 310.87M | 112.42M | 93.74M | 27.80M | 247.79M |
| Total Debt | 2.74B | 2.59B | 2.75B | 2.85B | 2.88B |
| Total Liabilities | 3.67B | 3.55B | 3.41B | 3.59B | 3.57B |
| Stockholders Equity | -70.79M | -109.27M | 19.78M | 298.42M | 360.34M |
Cash Flow | |||||
| Free Cash Flow | 269.93M | 220.11M | 276.39M | -25.50M | 194.09M |
| Operating Cash Flow | 339.99M | 295.10M | 345.58M | 65.10M | 241.82M |
| Investing Cash Flow | -112.26M | -63.00M | -69.19M | -174.31M | -194.18M |
| Financing Cash Flow | -31.53M | -211.79M | -212.57M | -106.62M | -138.12M |
Amneal Pharmaceuticals Technical Analysis
Positive
13.91
Price Trends
13.27
Positive
13.08
Positive
11.36
Positive
Market Momentum
0.10
Negative
66.88
Neutral
91.61
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 13.91 is above the 20-day moving average (MA) of 12.51, above the 50-day MA of 13.27, and above the 200-day MA of 11.36, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 66.88 is Neutral, neither overbought nor oversold. The STOCH value of 91.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.
Amneal Pharmaceuticals Risk Analysis
Amneal Pharmaceuticals disclosed 57 risk factors in its most recent earnings report. Amneal Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amneal Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.81B | 20.21 | 15.55% | ― | 43.78% | ― | |
61 Neutral | $964.18M | 12.76 | 12.76% | ― | -1.65% | -36.34% | |
58 Neutral | $4.01B | -64.92 | -67.91% | ― | 7.64% | ― | |
55 Neutral | $2.85B | -72.78 | -3.67% | ― | 8.63% | -150.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.58B | -1.35 | -35.16% | 8.48% | -2.75% | -761.90% | |
46 Neutral | $1.03B | -3.30 | -11.92% | ― | 26.02% | ― |
* Healthcare Sector Average
AMRX
Amneal Pharmaceuticals
12.74
5.07
66.25%
PRGO
Perrigo Company
11.51
-12.54
-52.14%
SUPN
Supernus Pharmaceuticals
48.69
16.21
49.91%
ANIP
ANI Pharmaceuticals
78.50
7.68
10.84%
AMPH
Amphastar Pharmaceuticals
21.82
-2.59
-10.61%
ALVO
Alvotech
3.52
-4.32
-55.10%
Amneal Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Amneal to Acquire Kashiv, Expanding Biosimilars Platform
Positive
Apr 22, 2026
On April 21, 2026, Amneal agreed to acquire 100% of Kashiv BioSciences for $375 million in cash, $375 million in stock and up to $350 million in milestone payments, plus royalties, in a deal expected to close in the second half of 2026 pending sha...
Business Operations and StrategyFinancial Disclosures
Amneal Posts Strong Q4 Results and Raises 2026 Outlook
Positive
Feb 27, 2026
On February 27, 2026, Amneal reported that fourth-quarter 2025 net revenue rose 11% year over year to $814 million, with GAAP net income swinging to a $35 million profit from a $31 million loss and adjusted EBITDA climbing 13% to $175 million. Spe...
Business Operations and StrategyPrivate Placements and Financing
Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs
Positive
Feb 3, 2026
On February 2, 2026, Amneal Pharmaceuticals’ subsidiary, Amneal Pharmaceuticals LLC, and certain of its subsidiaries entered into a second amendment to their November 14, 2023 term loan credit agreement, refinancing and partially converting ...
Business Operations and StrategyLegal Proceedings
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan
Negative
Jan 28, 2026
On January 23, 2026, Amneal Pharmaceuticals said it would implement a nationwide opioids settlement after securing sufficient participation from all eligible state and territorial attorneys general and all subdivisions that had sued the company, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.